Antibody-directed, effector cell-mediated tumor destruction

Preclinical and clinical development of antitumor strategies using mAbs are showing antitumor efficacy in animal models and in some clinical settings. Preclinical models suggest that mAb treatment would be most effective when provided in the minimal residual disease setting and can involve mAbs in a variety of roles. In murine models, the combination of mAbs with recombinant cytokines, such as IL-2, IL-12, or GM-CSF, can augment the immunologic effect of the mAbs by activating effector cell functions. Efficacy appears to be greatest when the mAb can recruit the effector cells of the host's immune system into helping in the mediation of the antitumor effect. Clinical testing of these concepts is under way.